Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition
Strengthening of the order book to 210,000 tons at end-June 2022: six new contracts signed, two of them abroad Creation of a first Joint Venture in Switzerland Acquisition of a grinding
Regulatory News: Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (Paris:ALHGR) ("Hoffmann Green Cement" or the "Company"), an industrial player committed to decarbonizing the
First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase III POLARIX study
Merck Animal Health researcher Sarah Hoffmann shares their new Hyper InfusiO₂n™ system that infuses the oxygen into the waters in and around fish ladders to make dam passage much safer and efficient.